TEG ®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care.
TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care.
Platelets. 2019 Dec 26;:1-7
Authors: Dias JD, Lopez-Espina CG, Bliden K, Gurbel P, Hartmann J, Achneck HE
Abstract
Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platelet counts were prepared from healthy voluntee...
Source: Platelets - December 28, 2019 Category: Hematology Tags: Platelets Source Type: research
Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis
ConclusionsRoutine GPI administration in STEMI resulted in a reduction in mortality, driven by reductions in recurrent ischemic events—however predominantly in pre-prasugrel/ticagrelor trials. Trials with contemporary STEMI management are needed to confirm these findings.RésuméContexteLes lignes directrices recommandent le traitement d’appoint par des inhibiteurs des glycoprotéines IIb-IIIa (IGP) uniquement chez certains patients ayant subi un infarctus du myocarde avec élévation du segment ST (STEMI) aigu. Cette étude visait à évaluer l’utilisation systématique des IGP chez les patients ayant subi un STEMI ...
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research
Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review
This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention. These drugs include oral antiplatelets (aspirin and P2Y12 inhibitors such as clopidogrel, prasugrel and ticagrelor), intravenous antiplatelet agents (the P2Y12 inhibitor cangrelor, GP IIb/IIIa inhibitors such as abciximab, eptifibatide and tirofiban), and intravenous anticoagulant agents (unfractionated heparin, low molecular weight heparin and bivalirudin).ResumoNeste artigo foram analisadas as princ...
Source: Revista Portuguesa de Cardiologia - June 13, 2019 Category: Cardiology Source Type: research
Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-Analysis
ConclusionsRoutine GPI administration in STEMI resulted in mortality reduction, driven by reductions in recurrent ischemic events – however predominantly in trials pre-prasugrel/ticagrelor. Trials in contemporary STEMI management are needed to confirm these findings. (Source: Canadian Journal of Cardiology)
Source: Canadian Journal of Cardiology - May 8, 2019 Category: Cardiology Source Type: research
Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
CONCLUSIONS: Eptifibatide, tirofiban, and cangrelor are preferred over abciximab as a perioperative bridge. The choice of agent should be tailored to clinical characteristics of the patient and institutional acquisition costs.
PMID: 30646761 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 16, 2019 Category: Drugs & Pharmacology Authors: Van Tuyl JS, Newsome AS, Hollis IB Tags: Ann Pharmacother Source Type: research
Pipeline Diameter Significantly Impacts the Long-Term Fate of Jailed Side Branches during Treatment of Intracranial Aneurysms [INTERVENTIONAL]
CONCLUSIONS:
A smaller Pipeline Embolization Device diameter is associated with delayed side branch stenosis/occlusion following Pipeline Embolization Device treatment, likely due to the higher metal density of smaller caliber devices. Although hemodynamic factors, including the potential for collateral flow, are still paramount in determining the fate of covered side branches, the amount of metal coverage at the side branch orifice also plays an important role. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - December 14, 2018 Category: Radiology Authors: Miller, T. R., Kole, M. J., Le, E. J., Cannarsa, G., Jones, S., Wessell, A. P., Jindal, G., Aldrich, E. F., Simard, J. M., Gandhi, D. Tags: INTERVENTIONAL Source Type: research
The Interaction of Cross-Linked Fibrin Fragment D-Dimer with {alpha}IIb{beta}3 Requires Receptor Activation, Occurs at Sites Other Than the {gamma}-404-411 Sequence, and Contributes to Clot Retraction
Conclusion: We conclude that cross-linked fibrin fragment D-dimer, like fibrinogen fragment 'D98', interacts with activated αIIbβ3 via sites other than the -404-411 peptide, and that this interaction contributes to clot retraction.DisclosuresColler: Rockefeller University: Patents & Royalties: RUC-4; Platelet Biogenesis: Consultancy; Centocor: Patents & Royalties: Abciximab; CeleCor: Consultancy, Equity Ownership; Accumetrics: Patents & Royalties: VerifyNow Assays; Scholar Rock: Consultancy, Equity Ownership. (Source: Blood)
Source: Blood - November 21, 2018 Category: Hematology Authors: Zafar, H., Li, J., Buitrago, C., Nesic, D., Coller, B. S. Tags: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Platelet Signaling and Interaction with the Microenvironment Source Type: research
Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of RUC-4 Succinate, a Novel {alpha}IIb{beta}3 Pure Antagonist for First Point of Contact Treatment of ST Segment Elevated Myocardial Infarction (STEMI)
We are developing the novel αIIbβ3 pure antagonist, RUC-4, for first point of contact treatment of ST Segment Elevated Myocardial Infarction (STEMI) in combination with aspirin. We have chosen the subcutaneous (SC) route to facilitate its delivery by ambulance and emergency room personnel, and potentially by self-administration. In preparation for initiating human studies, we have conducted preclinical studies of: 1. the pharmacokinetics (PK) and pharmacodynamics (PD) of RUC-4 succinate administered IV, IM, and SC to non-human primates (NHP); 2. the impact of in vitro aspirin on the RUC-4 IC50 in human platelet-...
Source: Blood - November 21, 2018 Category: Hematology Authors: Vootukuri, S., Li, J., Nedelman, M., Babayeva, M., Coller, B. S. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research
Targeting {beta}3 Integrin Psi Domain Inhibits Both Platelet Aggregation and Blood Coagulation: Two Birds with One Stone
Integrin αIIbβ3 plays key roles in thrombosis and hemostasis primarily through mediating platelet adhesion and aggregation. We recently reported that the active site of thiol-isomerase enzymes, CXXC motif, is expressed twice within the plexin-semaphorin-integrin (PSI) domain across all integrins and species, and the PSI domain of β3 integrin possesses endogenous thiol-isomerase activity, which may be a novel target for anti-thrombotic therapy (Blood, 2017).We developed four mouse anti-mouse β3 integrin PSI domain monoclonal antibodies (mAbs). These mAbs cross-react with β3 PSI domains of human, mo...
Source: Blood - November 21, 2018 Category: Hematology Authors: Stratton, T. W., Zhu, G., Wang, Y., Chen, P., Neves, M. A. D., Gallant, R. C., Norris, P. A. A., Freedman, J. J., Ni, H. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research
Fibrinolysis of Contracted Blood Clots Depends on Whether Plasminogen Activator Acts from inside or Outside
Fibrinolysis involves the dissolution of polymeric fibrin networks that is required to restore blood flow through vessels obstructed by clots and thrombi. The efficiency of lysis depends on the susceptibility of fibrin to enzymatic digestion, which is governed by the structure and spatial organization of fibrin fibers as well as porosity and composition of the clot. Platelet-driven clot contraction results in compaction of the erythrocytes into the core of the clot, effectively reducing the permeability of the clot, and influences fibrin network structure. We have shown that clot contraction is reduced in blood from patien...
Source: Blood - November 21, 2018 Category: Hematology Authors: Tutwiler, V., Peshkova, A. D., Le Minh, G., Zaitsev, S., Litvinov, R. I., Cines, D. B., Weisel, J. W. Tags: 321. Blood Coagulation and Fibrinolytic Factors: Poster III Source Type: research
Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.
CONCLUSIONS: IC versus IV abciximab did not enhance myocardial reperfusion in non-selected patients with STEMI undergoing primary PCI after aspiration thrombectomy had successfully been performed.
PMID: 30460974 [PubMed - as supplied by publisher] (Source: Cardiovascular Journal of Africa)
Source: Cardiovascular Journal of Africa - November 20, 2018 Category: Cardiology Authors: Bedjaoui A, Allal K, Lounes MS, Belhadi CE, Mekarnia A, Sediki S, Kara M, Azaza A, Monsuez JJ, Benkhedda S Tags: Cardiovasc J Afr Source Type: research
Intracoronary Tenecteplase versus Abciximab as Adjunctive Treatment during Primary Percutaneous Coronary Intervention in Patients with Anterior Myocardial Infarction.
CONCLUSIONS: Intracoronary administration of tenecteplase did not reduce infarct size compared to abciximab in STEMI patients undergoing PPCI. Tenecteplase exhibited poorer myocardial reperfusion and might be associated with increased subacute stent thrombosis.
PMID: 30418157 [PubMed - as supplied by publisher] (Source: EuroIntervention)
Source: EuroIntervention - November 13, 2018 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Use of Antiplatelet Agents in the Neurosurgical Patient
This article presents the relevant data supporting the use of antiplatelet agents in vascular neurosurgery and recommendations based on the described studies. (Source: Neurosurgery Clinics of North America)
Source: Neurosurgery Clinics of North America - September 15, 2018 Category: Neurosurgery Authors: Amanda S. Zakeri, Shahid M. Nimjee Source Type: research
Massive stent thrombosis during active ulcerative colitis: the tricky balance between manifest hemorrhagic and concealed thrombotic risk
We report the case of a 70-year-old man who presented with ST elevation myocardial infarction during the active phase of ulcerative colitis (UC). Because of the ongoing hematochezia, after successful revascularization of the culprit vessel, the patient was medicated with Clopidogrel, in place of one of the more powerful new oral P2Y12 inhibitors that currently represent the gold standard therapy. Few days later a second elective percutaneous coronary intervention (PCI) on a non-culprit vessel ensued in a life-threatening early massive stent thrombosis involving the left main. During and after emergency PCI antiplatelet the...
Source: Clinical and Experimental Medicine - August 22, 2018 Category: Research Source Type: research
